Immunic (NASDAQ:IMUX) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Immunic (NASDAQ:IMUX) in a report issued on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $17.00 price target on the stock.

Several other research analysts also recently issued reports on the company. Leerink Partners reaffirmed an “outperform” rating and set a $5.00 price target on shares of Immunic in a research note on Monday, September 9th. HC Wainwright began coverage on shares of Immunic in a research report on Monday, November 25th. They issued a “buy” rating and a $10.00 price target on the stock. EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a research note on Monday, September 16th. Leerink Partnrs raised Immunic to a “strong-buy” rating in a research report on Monday, September 9th. Finally, StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $12.67.

Immunic Price Performance

NASDAQ IMUX opened at $1.12 on Tuesday. The business has a 50 day moving average price of $1.14 and a 200 day moving average price of $1.32. The company has a market capitalization of $100.89 million, a P/E ratio of -0.91 and a beta of 1.88. Immunic has a 1-year low of $0.97 and a 1-year high of $2.11.

Insider Transactions at Immunic

In related news, Director Richard Alan Rudick acquired 87,300 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the acquisition, the director now directly owns 87,300 shares in the company, valued at approximately $100,395. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Immunic

A number of institutional investors have recently bought and sold shares of IMUX. State Street Corp boosted its holdings in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares during the last quarter. Virtu Financial LLC acquired a new position in Immunic in the third quarter valued at $50,000. Jane Street Group LLC increased its stake in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares during the period. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.